Wechselwirkungen · Vipdomet
Vipdomet 12.5 mg/850 mg film-coated tablets Vipdomet 12.5 mg/1 000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-128222 · Präparat HOS-096533
Medicinal products with intrinsic hyperglycaemic activity Glucocorticoids (given by systemic and local routes), beta-2-agonists and diuretics (see also section 4.4) have intrinsic hyperglycaemic activity. The patient should be informed and more frequent blood glucose monitoring performed, especially at the beginning of treatment with such medicinal products. If necessary, the dose of Vipdomet should be adjusted during therapy with the other medicinal product and upon its discontinuation.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glucose (HOS-088412)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-19T10:12:00Z · SHA-256 5d12ec426b99e14df8aa4c8f8038d545754cfbf664c9d4d39cfd1f4c32ded7f3 · Passage 09f8d3dc8be9e395f600855cd56e833e5b289b3f77461f9d287c37c7dd4b7c7e · Zeichen 2138–2630 im Abschnitt